388 related articles for article (PubMed ID: 31081566)
1. Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy.
Felipe C; Ferreira AN; de Paula M; Viana L; Cristelli M; Medina Pestana J; Tedesco-Silva H
Transpl Infect Dis; 2019 Dec; 21(6):e13106. PubMed ID: 31081566
[TBL] [Abstract][Full Text] [Related]
2. Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: A natural experiment.
Cristelli MP; Felipe CR; Prizmic PSS; de Azevedo VFD; Viana LA; Tavares MG; Wagner de Castro Lima Santos D; de Paula MI; Medina-Pestana JO; Tedesco-Silva Junior H
Clin Transplant; 2019 Oct; 33(10):e13689. PubMed ID: 31400155
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
Reusing JO; Feitosa EB; Agena F; Pierrotti LC; Azevedo LSF; Kotton CN; David-Neto E
Transpl Infect Dis; 2018 Oct; 20(5):e12929. PubMed ID: 29809309
[TBL] [Abstract][Full Text] [Related]
4. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients.
Cristelli MP; Esmeraldo RM; Pinto CM; Sandes-Freitas TV; Felipe C; Lobo CF; Viana L; Mansur J; Stopa S; Santos DWC; Grenzi PC; Aguiar WF; Tedesco-Silva H; Pestana JOM
Transpl Infect Dis; 2018 Aug; 20(4):e12907. PubMed ID: 29679515
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.
Bataille S; Moal V; Gaudart J; Indreies M; Purgus R; Dussol B; Zandotti C; Berland Y; Vacher-Coponat H
Transpl Infect Dis; 2010 Dec; 12(6):480-8. PubMed ID: 20629971
[TBL] [Abstract][Full Text] [Related]
6. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil in pancreas transplantation.
Gruessner RW; Sutherland DE; Drangstveit MB; Wrenshall L; Humar A; Gruessner AC
Transplantation; 1998 Aug; 66(3):318-23. PubMed ID: 9721799
[TBL] [Abstract][Full Text] [Related]
8. Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction.
Couzi L; Helou S; Bachelet T; Martin S; Moreau K; Morel D; Lafon ME; Garrigue I; Merville P
Transplant Proc; 2012 Nov; 44(9):2809-13. PubMed ID: 23146529
[TBL] [Abstract][Full Text] [Related]
9. The use of sirolimus in patients with recurrent cytomegalovirus infection after kidney transplantation: A retrospective case series analysis.
Shendi AM; Hung RKY; Caplin B; Griffiths P; Harber M
Saudi J Kidney Dis Transpl; 2019; 30(3):606-614. PubMed ID: 31249224
[TBL] [Abstract][Full Text] [Related]
10. Failure of ganciclovir prophylaxis to completely eradicate CMV disease in renal transplant recipients treated with intense anti-rejection immunotherapy.
Isenberg AL; Shen GK; Singh TP; Hahn A; Conti DJ
Clin Transplant; 2000 Jun; 14(3):193-8. PubMed ID: 10831076
[TBL] [Abstract][Full Text] [Related]
11. Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor.
Ferreira AN; Felipe CR; Cristelli M; Viana L; Mansur J; de Paula M; Wagner D; de Marco R; Gerbase-DeLima M; Proença H; Aguiar W; Medina-Pestana J; Tedesco-Silva Junior H
Transpl Int; 2019 Nov; 32(11):1127-1143. PubMed ID: 31278785
[TBL] [Abstract][Full Text] [Related]
12. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
Tedesco-Silva H; Felipe C; Ferreira A; Cristelli M; Oliveira N; Sandes-Freitas T; Aguiar W; Campos E; Gerbase-DeLima M; Franco M; Medina-Pestana J
Am J Transplant; 2015 Oct; 15(10):2655-64. PubMed ID: 25988935
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus infection in heart transplantation: A single center experience.
Echenique IA; Angarone MP; Rich JD; Anderson AS; Stosor V
Transpl Infect Dis; 2018 Aug; 20(4):e12896. PubMed ID: 29602266
[TBL] [Abstract][Full Text] [Related]
15. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients.
Luan FL; Samaniego M; Kommareddi M; Park JM; Ojo AO
Transpl Infect Dis; 2010 Dec; 12(6):473-9. PubMed ID: 20576019
[TBL] [Abstract][Full Text] [Related]
16. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
Lo A; Stratta RJ; Egidi MF; Shokouh-Amiri MH; Grewal HP; Kisilisik AT; Trofe J; Alloway RR; Gaber LW; Gaber AO
Transpl Infect Dis; 2001 Mar; 3(1):8-15. PubMed ID: 11429034
[TBL] [Abstract][Full Text] [Related]
17. [Factors influencing prevalence and clinical course of cytomegalovirus (CMV) infection in kidney transplant patients].
Szymczakiewicz-Multanowska AM; Kuźniewski M; Zawilińska B; Zgórniak-Nowosielska I; Uracz D; Ignacak E; Betkowska-Prokop A; Sułowicz W
Przegl Lek; 2001; 58(7-8):772-7. PubMed ID: 11769385
[TBL] [Abstract][Full Text] [Related]
18. Incidence of cytomegalovirus in cardiac transplant recipients receiving induction immunosuppression with antithymocyte globulin.
Jewani PK; Pouch SM; Kissling KT
Clin Transplant; 2018 Nov; 32(11):e13420. PubMed ID: 30290013
[TBL] [Abstract][Full Text] [Related]
19. The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis.
Basso G; Felipe CR; Cristelli MP; Mansur Siliano J; Viana L; Ferreira Brigido AN; Stopa Martins SB; de Castro Lima Santos DW; Aguiar WF; Tedesco-Silva Junior H; Medina-Pestana JO
Transpl Infect Dis; 2018 Aug; 20(4):e12919. PubMed ID: 29797676
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus infection after acute rejection therapy in seropositive kidney transplant recipients.
Lee YM; Kim YH; Han DJ; Park SK; Park JS; Sung H; Hong HL; Kim T; Kim SH; Choi SH; Kim YS; Woo JH; Lee SO
Transpl Infect Dis; 2014 Jun; 16(3):397-402. PubMed ID: 24810355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
